Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma

Previous anti-EGFR trials in unselected gastroesophageal adenocarcinoma (GEA) patients were resoundingly negative. We identified EGFR amplification in 5% (19/363) of patients at the University of Chicago, including 6% (8/140) who were prospectively screened with intention-to-treat using anti-EGFR th...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Discov
Egile Nagusiak: Maron, Steven B., Alpert, Lindsay, Kwak, Heewon A., Lomnicki, Samantha, Chase, Leah, Xu, David, O’Day, Emily, Nagy, Rebecca J., Lanman, Richard B., Cecchi, Fabiola, Hembrough, Todd, Schrock, Alexa, Hart, John, Xiao, Shu-Yuan, Setia, Namrata, Catenacci, Daniel V.T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984701/
https://ncbi.nlm.nih.gov/pubmed/29449271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-1260
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak